Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
36.13
+0.06 (0.17%)
Oct 6, 2025, 4:00 PM EDT - Market closed
Royalty Pharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover Royalty Pharma stock have a consensus rating of "Strong Buy" and an average price target of $44.5, which forecasts a 23.17% increase in the stock price over the next year. The lowest target is $40 and the highest is $54.
Price Target: $44.5 (+23.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +16.25% | Sep 30, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +16.25% | Jul 22, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $51 → $54 | Buy | Maintains | $51 → $54 | +49.46% | Jul 10, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $60 → $40 | Strong Buy | Maintains | $60 → $40 | +10.71% | Oct 25, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $50 → $51 | Strong Buy | Maintains | $50 → $51 | +41.16% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
3.06B
from 2.26B
Increased by 35.14%
Revenue Next Year
3.10B
from 3.06B
Increased by 1.24%
EPS This Year
4.59
from 1.91
Increased by 140.16%
EPS Next Year
5.12
from 4.59
Increased by 11.54%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.3B | 3.6B | |||
| Avg | 3.1B | 3.1B | |||
| Low | 2.3B | 2.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 46.6% | 16.2% | |||
| Avg | 35.1% | 1.2% | |||
| Low | 3.2% | -16.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.85 | 6.03 | |||
| Avg | 4.59 | 5.12 | |||
| Low | 4.30 | 4.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 153.7% | 31.3% | |||
| Avg | 140.2% | 11.5% | |||
| Low | 124.7% | -4.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.